EphA2 silencing in nasopharyngeal carcinoma leads to decreased proliferation, invasion and increased sensitization to paclitaxel

Oncology Letters

Volumn 4, Issue 3, 2012, Pages 429-434

  Tan, Pingqing ^a,b   Liu, Yong ^a,b   Yu, Changyun ^a,b   Su, Zhongwu ^a,b   Li, Guo ^a,b   Zhou, Xiaojuan ^c   Huang, Donghai ^a,b   Zhang, Xin ^a,b   Qiu, Yuanzheng ^a,b   Tian, Yongquan ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Otolaryngology Major Disease Research Key Laboratory of Hunan Province   (China)

^c Department of Otolaryngology   (China)

Author keywords

Drug resistance; EphA2; Metastasis; Nasopharyngeal carcinoma; Paclitaxel

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; EPHRIN RECEPTOR A2; PACLITAXEL; SHORT HAIRPIN RNA;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER STAGING; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIZATION; DRUG TARGETING; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MALE; MITOSIS INHIBITION; NASOPHARYNX CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

EID: 84863862469     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.746     Document Type: Article

References (30)

1. Fahraeus R, Fu HL, Ernberg I, et al: Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42: 329-338, 1988.
2. Shanmugaratnam K: Nasopharyngeal carcinoma: epidemiology, histopathology and aetiology. Ann Acad Med Singapore 9: 289-295, 1980.
3. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
4. Teo P, Shiu W, Leung SF and Lee WY: Prognostic factors in nasopharyngeal carcinoma investigated by computer tomography-an analysis of 659patients. Radiother Oncol 23: 79-93, 1992.
5. Tan EH, Khoo KS, Wee J, et al: Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 10: 235-237, 1999.
6. Pasquale EB: Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10: 165-180, 2010.
7. Pasquale EB: Eph-ephrin bidirectional signaling in physiology and disease. Cell 133: 38-52, 2008.
8. Sulman EP, Tang XX, Allen C, et al: ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics 40: 371-374, 1997.
9. Brantley-Sieders DM, Zhuang G, Hicks D, et al: The receptor tyrosine kinase EphA2promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2signaling. J Clin Invest 118: 64-78, 2008.
10. Lu C, Shahzad MM, Wang H, et al: EphA2overexpression promotes ovarian cancer growth. Cancer Biol Ther 7: 1098-1103, 2008.
11. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR and KinchMS: EphA2overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-2306, 2001.
12. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R and Kinch MS: E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10: 629-638, 1999.
13. Lin YG, Han LY, Kamat AA, et al: EphA2overexpression is associated with angiogenesis in ovarian cancer. Cancer 109: 332-340, 2007.
14. Han L, Dong Z, Qiao Y, et al: The clinical significance of EphA2and Ephrin A-1in epithelial ovarian carcinomas. Gynecol Oncol 99: 278-286, 2005.
15. Brannan JM, Dong W, Prudkin L, et al: Expression of the receptor tyrosine kinase EphA2is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 15: 4423-4430, 2009.
16. Liu F, Park PJ, Lai W, et al: A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res 66: 10815-10823, 2006.
17. Taddei ML, Parri M, Angelucci A, et al: EphA2induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells. Mol Cancer Res 9: 149-160, 2011.
18. Herrem CJ, Tatsumi T, Olson KS, et al: Expression of EphA2is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 11: 226-231, 2005.
19. Liu Y, Xie C, Zhang X, et al: Elevated expression of HMGB1in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 46: 3007-3015, 2010.
20. Liu Y, Zhang X, Qiu Y, et al: Clinical significance of EphA2expression in squamous-cell carcinoma of the head and neck. J Cancer Res Clin Oncol 137: 761-769, 2011.
21. Johnson FM, Garden AS, Palmer JL, et al: A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 63: 717-724, 2005.
22. Liu Y, Yu C, Qiu Y, et al: Downregulation of EphA2expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo. J Cancer Res Clin Oncol 138: 195-202, 2012.
23. Zhu G, Xiao D, Chen Q and Zhu Y: The expression and its potentially clinical significance of EphA2in nasopharyngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi25: 827-829, 833, 2011 (In Chinese).
24. Abraham S, Knapp DW, Cheng L, et al: Expression of EphA2and Ephrin A-1in carcinoma of the urinary bladder. Clin Cancer Res12: 353-360, 2006.
25. Brannan JM, Sen B, Saigal B, et al: EphA2in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2: 1039-1049, 2009.
26. Kinch MS, Moore MB and Harpole DH Jr: Predictive value of the EphA2receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9: 613-618, 2003.
27. King AD, Ahuja AT, Leung SF, et al: Neck node metastases from nasopharyngeal carcinoma: MR imaging of patterns of disease. Head Neck 22: 275-281, 2000.
28. Leung SF, Teo PM, Shiu WW, Tsao SY and Leung TW: Clinical features and management of distant metastases of nasopharyngeal carcinoma. J Otolaryngol 20: 27-29, 1991.
29. Ciuleanu TE, Fountzilas G, Ciuleanu E, Plataniotis M, Todor N and Ghilezan N: Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study. J BUON 9: 161-165, 2004.
30. Landen CN Jr, Chavez-Reyes A, Bucana C, et al: Therapeutic EphA2gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65: 6910-6918, 2005.